載入...
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
BACKGROUND: Gliomas are the most common primary brain tumors. High-Grade Gliomas have a median survival (MS) of 18 months, while Low-Grade Gliomas (LGGs) have an MS of approximately 7.3 years. Seventy-six percent of patients with LGG express mutated isocitrate dehydrogenase (mIDH) enzyme. Survival o...
Na minha lista:
| 發表在: | Neurooncol Adv |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7212865/ https://ncbi.nlm.nih.gov/pubmed/32642696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa042 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|